BPCE
NVCR icon

Bank Pictet & Cie (Europe)’s NovoCure NVCR Stock Holding History

Bank Pictet & Cie (Europe)’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,661
Closed -$951K – 184
2021
Q4 		$951K Buy
+12,661
New +$1.27M 0.03% 107

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Pictet & Cie (Europe)'s NVCR Position: Q1 2022 in Review

Bank Pictet & Cie (Europe) sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 12,661 shares — an estimated $951K sold.

Bank Pictet & Cie (Europe) first reported a position in NVCR in Q4 2021 and held it in 1 quarter. The position peaked at $951K in Q4 2021. 309 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

  • Bank Pictet & Cie (Europe) reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
  • Bank Pictet & Cie (Europe) sold 12,661 NovoCure shares in Q1 2022, an estimated $951K.
  • Bank Pictet & Cie (Europe) first reported a position in NovoCure in Q4 2021 and held it in 1 quarter.
  • Bank Pictet & Cie (Europe)'s NovoCure position peaked at $951K in Q4 2021.
  • 309 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Bank Pictet & Cie (Europe)'s 13F filing for Q1 2022, filed 4 May 2022.